Best Life Sciences Companies in Ghent, Belgium
The 37 best Life Sciences companies in Ghent, Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AgomAb Therapeutics.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Ghent
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | AgomAb Therapeutics Developer of monoclonal antibody molecules for multiple disorders | $327M | 22 mo ago | 23 | Tim Knotnerus CEO | WordPressApple iCloud MailMicrosoft 365+27 | 34 patents MET receptor antibody therapeutics and pancreatic islet cell regeneration technologies | — |
| 2 | Devgen An agritech company developing hybrid seeds and crop protection solutions | $71M | 68 mo ago | 35 | Bipin Solanki CEO | — | 459 patents RNAi-based biopesticides and RNA preservation technologies for insect and plant pest control | — |
| 3 | argenx Developer of antibody-based drugs to treat autoimmune diseases and cancer | $62M | 53 mo ago | 355 | — | Adobe Experience ManagerApple iCloud MailJava+17 | 372 patents Therapeutic antibodies targeting FcRn and neuromuscular antigens for immune disorders | 1 launch |
| 4 | ActoGeniX Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides. | $57M | 160 mo ago | 5 | — | — | 143 patents Patents concentrated in health & consumer products | — |
| 5 | Indigo Needle free glucose monitoring technology | $53M | 35 mo ago | 33 33 → 34 (+3%) | Danaë Delbeke CEO | WordPressApple iCloud MailMicrosoft 365+20 | — | — |
| 6 | ExeVir Bio Provider of antibody-based therapies to monitor viral infections | $50M | 44 mo ago | 11 | — | WordPressMySQLPHP+19 | 23 patents Design of protein binders that block coronavirus spike S2 subunit for antiviral therapy | — |
| 7 | Dualyx Developer of immune modulators for treating auto-immune diseases | $43M | 40 mo ago | 7 | Luc Van Rompaey Founder | — | 5 patents Therapeutic binding proteins targeting interleukin receptors for immune modulation | — |
| 8 | Pronota Provider of diagnostics for heart failure, pre-eclampsia, and sepsis | $35M | 165 mo ago | 2 | — | — | 107 patents Patents concentrated in computing, sensing & instrumentation | — |
| 9 | MyCartis Provider of bio-marker discovery platform for immunodiagnostics | $20M | 144 mo ago | 2 | — | — | 127 patents Encoded microcarriers for multiplexed biological/chemical assay platforms | — |
| 10 | Inbiose Contract manufacturer of specialty carbohydrates | $18M | 62 mo ago | 43 43 → 59 (+37%) | — | Webflow EcommerceWebflowcore-js+11 | 338 patents Enzymatic engineering of customized sialylated and fucosylated oligosaccharides for biotech applications | — |
| 11 | MRM Health Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases | $15M | 3 mo ago | 43 43 → 43 (+0%) | Sam Possemiers Founder & CEO | particles.jsBootstrapNginx+10 | 25 patents Therapeutic probiotic microbial formulations for liver disease, joint inflammation, and overall health | — |
| 12 | Ontoforce Provider of semantic search platform for pharmaceutical and biotech research | $13M | 103 mo ago | 31 31 → 34 (+10%) | — | HubSpot CMS HubAmazon Web ServicesMicrosoft Clarity+29 | 23 patents ETL automation and search‑facet data curation for enterprise information systems | 1 job opening |
| 13 | Morrow Eyewear Provider of auto focal lens for refractive errors in eyes | $10M | 50 mo ago | 37 37 → 19 (-49%) | Paul Marchal Founder & CEO | Wix eCommerceCart FunctionalityWix+20 | — | — |
| 14 | Azalea Vision Developer of technology for people with high light sensitivity and ocular disorders | $9M | 16 mo ago | 7 | — | WordPressMySQLPHP+25 | 6 patents Patents concentrated in transport & manufacturing processes | — |
| 15 | Trince Developer of cell transfection machinery | $5M | 57 mo ago | 3 | Kevin Braeckmans Co-founder and CSO/CTO | WordPressMySQLPHP+19 | 19 patents Patents concentrated in chemistry & materials | — |
| 16 | Biogazelle Transcriptomics-based diagnostics and therapeutics, and qPCR software. | $4M | 80 mo ago | 20 | — | — | 5 patents Patents concentrated in chemistry & materials | — |
| 17 | ADx NeuroSciences Biomarker assays for neurodegenerative diseases | $3M | 82 mo ago | 14 14 → 12 (-14%) | — | WordPressMySQLPHP+22 | 7 patents Biomarker assays and therapeutic antibodies targeting tau for neurodegenerative disease diagnosis and treatment | — |
| 18 | RheaVita Developer of an instrument for continuous freeze drying | $3M | 63 mo ago | 4 | Jos Corver Co-Founder | HubSpot CMS HubHubSpot ChatMicrosoft 365+12 | 20 patents Advanced freeze‑drying and cryogenic processing equipment for liquid mixtures | — |
| 19 | Molecubes Developer of solutions for preclinical benchtop imaging | $2M | 128 mo ago | 16 | Ewout Vansteenkiste Co Founder - Board of Directors | WordPressAlgoliaMySQL+23 | 10 patents Provides heating pads for animals and stationary SPECT imaging systems with crystal detector calibration. | — |
| 20 | Eyeco Display and eyewear technology for presbyobia | $2M | 123 mo ago | — | Jelle Smet Co-Founder | — | — | — |
| 21 | Biolizard Provider of a software solution for bioinformatics | $1M | 79 mo ago | 22 22 → 49 (+123%) | Gerben Menschaert Co-Founder | WordPressPleskMySQL+29 | — | — |
| 22 | Bio INX Provider of diverse 3D printing inks | $501K | 47 mo ago | — | Agnes Dobos Co-Founder | Cart FunctionalityDrupalPHP+12 | — | 1 partnership |
| 23 | OhmX.bio Provider of research platform for research purposes | $201K | 83 mo ago | 4 | Gerben Menschaert CSO & Co-Founder | WordPressMySQLPHP+34 | — | — |
Top 12 Life Sciences companies in Ghent
#1
Series B · Ghent, Flanders · founded 2020 · 43 employees$15.1Mraised▾
Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases. The company utilizes a proprietary platform to design and manufacture microbial therapeutics. Optimized consortia are developed through a bioinformatics-guided discovery engine. The company focuses on creating therapeutics with disease-modifying potential. Clinical programs include inflammatory bowel diseases, with preclinical programs in CNS and metabolic diseases. The company features end-to-end development capabilities, from discovery to clinical development.
- Sep 2025Series B$64.1M
- Feb 2020Series B$15.1M
#2
Public · Ghent, Flanders · founded 2017 · 23 employees$327Mraised▾
Developer of monoclonal antibody molecules for multiple disorders. The company has developed the monoclonal antibody molecules called agomAbs which stimulates the molecular and cellular repair mechanisms. It helps in organ function for patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases.
- Oct 2024Series D$89M
- Oct 2023Series C$100M
- Jul 2022Series B$40.5M
- Mar 2021Series B$74M
#3
Series A · Ghent, Flanders · founded 2018 · 7 employees$9.4Mraised▾
Developer of technology for people with high light sensitivity and ocular disorders. The company has developed an active light management system, embedded inside a contact lens. It helps in the treatment of iris deficiencies, high order aberrations, light sensitivity, and photophobia.
- Apr 2025Series A$10.3M
- Jul 2021Grant (prize money)$2.1M
- Jul 2021Series A$9.4M
#4
Series B · Ghent, Flanders · founded 2016 · 33 employees$52.6Mraised▾
Indigo is developing a needle-free continuous glucose monitoring technology using photonics technologies. Indigo is based in Ghent, Belgium, where it benefits from access to Ghent University and more specifically the Photonics Research Group and the NB-Photonics consortium.
- Oct 2023Grant (prize money)$865.2K
- Jul 2020Series B$44.3M
- Jul 2018Grant (prize money)$2.9M
- Dec 2016Series A$7.3M
#5
Series A · Ghent, Flanders · founded 2020 · 11 employees$49.6Mraised▾
Provider of antibody-based therapies to monitor viral infections. It has developed VHH that are single-domain antibody fragments derived from camelids. Its lead product VHH72-FC helps to bind conserved regions on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. It helps to stop the infection and viral replication supports the patient’s immune response by reducing the viral load and dampening local and systemic inflammation.
- Jan 2023Venture Debt$26.6M
- Dec 2021Grant (prize money)$6.8M
- Mar 2021Series A$22.7M
- Jul 2020Series A$27M
#6
Series A · Ghent, Flanders · founded 2019 · 7 employees$43.4Mraised▾
Developer of immune modulators for treating auto-immune diseases. Its lead candidate DT-001 is modulating the immune suppression target TNF receptor 2, DT-002 is an antibody, and DT-003 is targeting a new immunological pathway used for the treatments of autoimmune diseases.
- May 2023Series A$43.4M
- Mar 2020Seed—
#7
Public · Ghent, Flanders · founded 2008 · 355 employees$61.9Mraised▾
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llama's and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
- Mar 2022Post IPO$700M
- May 2020Post IPO$862M
- Nov 2019Post IPO$484M
- May 2015Grant (prize money)$1.7M
#8
Acquired · Ghent, Flanders · founded 1997 · 35 employees$71Mraised▾
An agritech company developing hybrid seeds and crop protection solutions. It is a provider of biotechnology solutions for crop protection and environmental stress tolerance. They offer innovative products to the agricultural industry.
- Jan 2021Grant (prize money)$50.8K
- Feb 2007Post IPO$40.3M
- Jul 2000Post IPO$5.8M
- Oct 1999Post IPO$24.8M
#9
Acquired · Ghent, Flanders · founded 2006 · 5 employees$57.2Mraised▾
ActoGeniX is focused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases. Its proprietary TopAct platform developed enables the molecular engineering of food-grade microbes (lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. Its clinical stage products include AG013 which delivers a therapeutic peptide for the prevention and attenuation of oral mucositis, and AG014 which secretes anti-TNF-alpha Fab to treat inflammatory bowel disease with localized delivery minimizing systemic exposure. Acobiotics has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases. The company has been acquired by Intrexon Corp. on Feb 2015.
- Apr 2013Series B$14M
- Feb 2009Series A$17.4M
- Jul 2007Grant (prize money)$4.2M
- Feb 2007Series A$25.8M
#10
Acqui-Hired · Ghent, Flanders · founded 2004 · 2 employees$34.7Mraised▾
Pronota NV provides diagnostics for early detection of medical conditions such as heart failure, pre-eclampsia, and sepsis. The company’s product is a non-invasive, validated, diagnostics are proprietary for patients. The company is exploring the proteomes of biological samples to build a portfolio of diagnostic products. The company is focussed in diagnosis and personalized healthcare.
- Dec 2012Series C$1.8M
- Jan 2012Series C$4.7M
- May 2010Series B$1.9M
- Jan 2010Grant (prize money)$2M
#11
Funding Raised · Ghent, Flanders · founded 2013 · 43 employees$18Mraised▾
Inbiose is engaged in offering contract manufacturing of specialty carbohydrates. Specialty carbohydrates are used in cosmetics, nutraceutical prebiotics, pharmaceutical APIs, agriculture, and animal health products. Services offered include biological system feasibility studies, development of upstream fermentation protocols, fermentation optimization, downstream process design and development, and research and manufacturing contracts.
- Jul 2021Conventional Debt$17.7M
- Jan 2019Grant (prize money)$293.8K
#12
Series A · Ghent, Flanders · founded 2016 · 37 employees$10Mraised▾
Provider of auto focal lens for refractive errors in eyes. It offers a lens based on self-assessment which is developed using liquid crystal technology.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Ghent is moving
A read on the academic research around Biotechnology in Ghent — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 62 papers.
- Ghent University57
- Ghent University Hospital10
- Cancer Research Institute Ghent4
- University College Ghent1
- T cell2
- Flow cytometry2
- Immune system2
- Transcription (linguistics)1
- Transcription factor1
- Gene4
- RNA interference3
- RNA silencing3
- Antibiotic resistance2
- Biofilm2
- Nematology2
- Heat stress2
- Fight-or-flight response2
- Livestock2
- Antimicrobial2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.